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Abstract: Systemic lupus erythematosus (SLE) is a chronic multi-organ autoimmune disease
characterized by hyperactivated immune responses to self-antigens and persistent systemic
inflammation. Previously, we reported abnormalities in circulating and bone marrow (BM)-derived
plasmacytoid dendritic cells (pDCs) from SLE patients. Here, we aim to seek for potential regulators
that mediate functional aberrations of pDCs in SLE. BM-derived pDCs from NZB/W F1 mice
before and after the disease onset were compared for toll-like receptor (TLR) induced responses
and microRNA profile changes. While pDCs derived from symptomatic mice were phenotypically
comparable to pre-symptomatic ones, functionally they exhibited hypersensitivity to TLR7 but not
TLR9 stimulation, as represented by the elevated upregulation of CD40, CD86 and MHC class
II molecules upon R837 stimulation. Upregulated induction of miR-155 in symptomatic pDCs
following TLR7 stimulation was observed. Transfection of miR-155 mimics in pre-symptomatic pDCs
induced an augmented expression of Cd40, which is consistent with the increased CD40 expression in
symptomatic pDCs. Overall, our results provide evidence for miR-155-mediated regulation in pDC
functional abnormalities in SLE. Findings from this study contribute to a better understanding of SLE
pathogenesis and ignite future interests in evaluating the molecular regulation in autoimmunity.
Keywords: systemic lupus erythematosus; plasmacytoid dendritic cells; microRNAs; toll-like
receptor 7
1. Introduction
Plasmacytoid dendritic cells (pDCs) constitute a unique subset of dendritic cells that have
important immunoregulatory functions and play critical roles in autoimmunity. Similar to conventional
or myeloid dendritic cells, pDCs upregulate the expressions of MHC class II antigen presentation
molecules and T-cell costimulatory molecules such as CD80, CD86 and CD40 upon antigen stimulation,
and serve as antigen presenting cells. Distinctively, pDCs specialize in producing type I interferon
(IFN) [1]. pDCs express high levels of endosomal TLR7 and TLR9 which are the respective sensors
for single stranded RNA and hypomethylated CpG DNA. Coupled with constitutive expression of
the transcription factor interferon regulatory factor 7 (IRF7), pDCs are capable of rapidly secreting
several hundred times more type I IFN than other leukocytes in response to viral or nucleic acids
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stimulations [2]. These unique features have granted pDCs a crucial role in the pathogenesis of systemic
lupus erythematosus (SLE), a disease with multi-organ inflammatory manifestations mediated by
autoantigens-autoantibodies immune complexes [3]. In human lupus disease, the role of pDCs
is often inferred by the elevated serum level of IFN-α and upregulation of type I IFN-sensitive
genes, which have been shown to correlate or associate with disease manifestations including the
SLE hallmark anti-dsDNA autoantibodies, and the involvement of renal, hematological and central
nervous systems [4–6]. Recent findings in animal studies, however, have specifically delineated pDCs’
functional contribution in SLE development. In the BXSB model, an early and transient depletion of
pDCs before disease onset resulted in amelioration in lupus-associated pathology, which coincided with
a reduced IFN-α/β-induced genes transcription [7]. Similar protective effects were also observed in
Tcf4-haplodeficient Tlr7 transgenic and B6.Sle1.Sle3 lupus models in which the pDCs were functionally
impaired by suppressing the E2-2 transcription factor [8].
In rheumatic diseases, a growing attention has been drawn to microRNAs (miRNAs) for their
critical role in regulating immune cell functions [9,10]. These small non-coding RNA molecules
post-transcriptionally regulate gene expression through complementary binding to their target
messenger RNAs, leading to mRNA degradation or translation repression. Many regulatory miRNAs
have been shown to link with SLE [11]. One interesting example is miR-146a. Its expression in
peripheral blood mononuclear cells (PBMCs) of SLE patients negatively correlates with disease activity
and IFN-sensitive genes expression [12]. Mechanistically, miR-146a acts as a negative regulator of type
I IFN production by targeting multiple signaling components downstream of TLR7/9 and the retinoic
acid-inducible gene-I pathways, thus its downregulated expression in lupus leukocytes promotes
IFN-α production [12–14]. In addition, TLR7/9 and IFN-α stimulation of PBMCs induces miR-146a
expression and apparently this negative feedback loop in IFN-α signaling pathway is dysfunctional
in SLE patients [12]. Whether miR-146a-mediated IFN-α regulation is perturbed in lupus pDCs is
unknown since there is no report on pDC-specific miRNA dysregulation in SLE so far. Nevertheless,
a few recent studies have described the involvement of miR-155, miR-126, miR-29b, and miR-29c in
regulating the functions of pDC in response to TLRs stimulation [15–17].
We previously demonstrated aberrations in frequencies, phenotypes and functions in DC subsets
in SLE patients [18–20]. Intriguingly, bone marrow (BM)-derived pDCs from SLE patients were also
found to have enhanced T-cell stimulatory ability and activated phenotypes [20], suggesting that
abnormalities could originate from their precursors. Indeed, defects in BM and hematopoietic stem
cells (HSCs) are also common in SLE patients [21–23]. Using the New Zealand Black/White F1 hybrid
(NZB/W F1) lupus mouse model which mimics the spontaneous and multifactorial nature of human
SLE disease, the present study aims to evaluate if SLE disease would impact on the generation and
functional responses of BM-derived pDCs; and secondly to identify potential miRNA regulators in
mediating functional irregularities in response to TLR stimulation.
2. Results
2.1. Lupus Disease Has Limited Impact on Plasmacytoid Dendritic Cells (pDC) Generation Potential of Bone
Marrow (BM) Progenitor Cells in NZB/W F1 Mice
To evaluate if the disease status in lupus has any effect on the development of pDCs, we isolated
BM cells from the NZB/W F1 mice before (pre-symptomatic) and after (symptomatic) the onset of
lupus symptoms for in vitro pDCs generation. In mice, the HSCs in BM are phenotypically identified
as Lineage´ (Lin´), Sca-1+ and c-Kit+ (LSK) cells and from which the progenitors of pDCs arise [24].
We analyzed the total numbers of BM cells as well as the frequencies of LSK cells from both groups
of mice (Figure 1A). Consistently, an average of (2.4 ˘ 0.7) ˆ 107 and (2.3 ˘ 0.8) ˆ 107 of total BM
cells could be harvested from the pre-symptomatic and symptomatic mice respectively. The LSK
frequencies in the total BM cells varied from 0.27% to 0.85% in the pre-symptomatic mice, and from
0.18% to 1.7% in the symptomatic mice. Overall, lupus disease did not have significant effect on the
total number of BM cells or the LSK frequency in NZB/W F1 mice.
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Figure 1. Gross development of pDCs is not affected by lupus. (A) Total numbers of bone marrow
(BM) cells and frequencies of hematopoietic stem cells, marked by Lineage´ (Lin´) Sca-1+c-Kit+
(LSK), from pre-symptomatic (Pre-sym) and symptomatic (Sym) mice were compared. Collective
data from more than 10 independent experiments, totaling n = 16–20 in the respective charts shown.
Each symbol represents one mouse; (B) Cells generated from Flt3-ligand-supplemented BM culture at
day-8 were analyzed. The expression of CD11c and B220 on live-gated cells as well as the expression
of CD317 and Siglec-H on CD11c+B220+- or CD11c+B220hi-gated cells are shown in representative
contour plots. Isotype antibodies control was used for the gating of CD317 and Siglec-H positive cells.
Numbers shown are the percent of double positive cells; (C) Collective data from at least 3 independent
experiments on the total numbers and frequencies of CD11c+B220hi pDCs in the pre-symptomatic and
symptomatic BM cultures are presented. Each symbol represents one mouse (n = 12).
Cells derived from 8-day Flt3 ligand BM culture were evaluated for pDC generation.
Mouse pDCs express the common DC marker CD11c and the B-cell lineage marker B220 [25].
Additionally, the BM stromal cell antigen 2 (BST2), also known as CD317 or PDCA-1, and the sialic
acid-binding immunoglobulin (Ig)-like lectin H (Siglec-H) are specifically expressed on mouse pDCs
at steady state [26,27]. Among these four markers, the former two can also be found on other immune
cells while the expression of the latter two fluctuates upon stimulation. Therefore, a combination of
CD11c, B220, CD317 and Siglec-H was used to identify pDCs from the heterogeneous BM culture
(Figure 1B). The BM-derived DC culture constituted a mixture of cell populations expressing variable
levels of these markers. Gating on the CD11c+B220+ cells, there remained a substantial proportion
of cells that were CD317´ and/or Siglec-H´. In contrast, the CD11c+B220hi subset were over 95%
CD317+Siglec-H+, representing a more homogenous pDC population. Overall, approximately 20%
of the cells generated from the Flt3 ligand-supplemented BM culture were CD11c+B220hi pDCs.
The frequencies as well as the total numbers of pDCs generated from the pre-symptomatic and
symptomatic BM cells were comparable (Figure 1C).
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2.2. BM-Derived pDCs Display Similar Phenotypes Irrespective of Lupus Disease Stage
Next, the surface expression of MHC class II and costimulatory molecules CD40 and CD86 were
analyzed. Consistent with the reported pDC phenotypes at steady state [25,28], CD11c+B220hi pDCs
expressed moderate level of MHC class II and very low levels for CD40 and CD86 (Figure 2A),
and similar expression levels of these markers were observed between pre-symptomatic and
symptomatic mice. Using quantitative RT-PCR, the expressions of Tlr7, Tlr9 and Irf7 were also
compared as they are constitutively expressed by pDCs and are essential to pDC functions. As shown
in Figure 2B, no significant difference in Tlr9 or Irf7 expression was observed between the two groups.
Interestingly, the pDCs derived from symptomatic mice displayed a small but significant increase in
Tlr7 expression when compared with the pre-symptomatic counterparts. However, further examination
of TLR7 and TLR9 protein revealed high constitutive expression in these cells but no significant
difference was observed between the two groups of pDCs (Figure 2C,D). In addition, the expression
of three classical IFN-stimulated genes (ISGs) including IFN-induced protein with tetratricopeptide
repeats 1 (Ifit1), IFN-inducible transmembrane protein 3 (Ifitm3) and 2151-oligoadenylate synthetase 1
(Oas1) were examined to check for any basal induction of type I IFN in lupus pDCs [29].
Among the three ISGs tested, no detectable expression was observed for Ifit1 and Oas1 (data not
shown). Expression of Ifitm3 was detectable but again there was no significant difference between
the two groups of pDCs (Figure 2B). Seemingly, these results appear to contradict to the established
role of type I IFN in SLE. A recent report has demonstrated in disease NZB/W F1 mice the elevated
expression of IFN signature genes such as Mx1, Ifit2 and Cxcl10 in pDCs isolated from spleen and BM,
thus supporting the involvement of type I IFN in this murine model [30]. Likely, these differentiated
pDCs have been continuously exposed to and stimulated by TLR7/9-activating immune complexes
in vivo. In contrast, in our system, BM pDC precursors were cultured in vitro with Flt3L, which is
known to promote pDC differentiation but not activation. It is likely that these BM-derived pDCs did
not spontaneously produce IFNα in culture and thus had limited basal or increase in the expression of
the ISGs. Overall, these data suggested that in vitro pDC development from BM cells was not grossly
affected by the development of lupus.
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CD11c+B220hi pDCs derived from day-8 BM culture were analyzed. Representative plots of n = 6–7 is 
shown; (B) Expression of Irf7, Tlr9, Tlr7 and Ifitm3 of purified pDCs derived from day-8 BM culture 
were examined by real time PCR, and were shown as relative quantities (RQ) with reference to the 
average expression of corresponding genes in the pre-symptomatic pDCs. Collective data of n = 6–7 
mice were shown; (C) Expressions of TLR7 and TLR9 in BM-derived pDCs on day-8 were analyzed. 
Numbers shown are percentages of positive cells. Shaded histograms represent isotype antibody 
staining controls; (D) Collective data comparing the mean fluorescence intensity (MFI) of TLR7 and 9 
expressed in pre-symptomatic and symptomatic pDCs. Each symbol represents one individual mouse 
(n = 6). Data were collected from at least three independent experiments. Bar: mean values; * p ≤ 0.05 
(unpaired two-tailed Student’s t-test). 
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were clearly upregulated in both groups; and importantly, the induction was significantly higher in 
symptomatic mice (Figure 3). As depicted in Figure 3, pDCs from symptomatic group expressed 
augmented levels of MHC class II, and the percentage of cells expressing CD40 and CD86 was also 
significantly higher. In contrast to TLR7 response, no significant difference was observed in the 
induction of MHC class II, CD40 or CD86 expression upon TLR9 activation via CpG (Supplementary 
Figure S1). Additionally, TLR7/9-mediated IL-6 and IFN-α production was also compared. Similar 
amount of interleukin (IL)-6 was secreted by R837-activated pDCs from the two groups of mice 
(Supplementary Figure S2). Surprisingly, no detectable IFN-α was observed in the culture 
supernatant from R837-stimulated pDCs, whereas these pDCs were capable of producing IFN-α 
upon CpG stimulation. R837 is an imidazoquinoline amine analog to guanosine that commonly used 
for evaluation of TLR7 mediated IFN-α response in human cells and likely, R837 is inefficient in 
activating type I IFN production in mice [31,32]. 
Apart from disease status, the age difference between the pre-symptomatic and symptomatic 
NZB/W F1 mice could have contributed to the differential TLR7 response. To evaluate this, R837 
responses of pDCs derived from parental non-lupus NZW young (12–16 weeks old) and old  
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observed between the two groups. These results suggested that the elevated R837 response in 
symptomatic NZB/W F1 group was not likely attributed by the age factor. 
Figure 2. Bone marrow-derived pDCs from pre-symptomatic (Pre-sym) and symptomatic (Sym) lupus
mice have similar phenotypes. (A) Expressions of MHC class II, CD40 and CD86 in CD11c+B220hi
pDCs derived from day-8 BM culture were analyzed. Representative plots of n = 6–7 is shown;
(B) Expression of Irf7, Tlr9, Tlr7 and Ifitm3 of purified pDCs derived from day-8 BM culture were
examined by real time PCR, and were shown as relative quantities (RQ) with reference to the average
expression of corresponding genes in the pre-symptomatic pDCs. Collective data of n = 6–7 mice were
shown; (C) Expressions of TLR7 and TLR9 in BM-derived pDCs on day-8 were analyzed. Numbers
shown are percentages of positive cells. Shaded histogram represent isotype antibody staining
controls; (D) Collective data comparing the ean fluorescence intensity (MFI) of TLR7 and 9 expressed
in pre-symptomatic and symptomatic pDCs. Each symbol r presents o e individual mouse
(n = 6). Data were collected from at least three independent experiments. Bar: mean values; * p ď 0.05
(unpaired two-tailed Student’s t-test).
2.3. BM-Derived pDCs from Symptomatic Lupus Mice Show Heightened TLR7-Mediated Antigen Presentation
and Costimulatory Mol c les Expressions
To examine the functional responses of pDCs, purified CD11c+B220hi cells were activated by
TLR agonists and compared. Upon R837 (TLR7 agonist) stimulation, MHC class II, CD40 as well
as CD86 were clearly upregulated in bo groups; and importantly, the induction was significantly
higher in symptomatic mice (Figure 3). As depicted in F gure 3, pDCs from symptomatic group
expressed augmented levels of MHC class II, and the percentage of cells expressing CD40 and
CD86 was also significantly higher. In contrast to TLR7 response, no significant difference was
observed in the induction of MHC class II, CD40 or CD86 expression upon TLR9 activation via CpG
(Supplementary Figure S1). Additionally, TLR7/9-mediated IL-6 and IFN-α production was also
compared. Similar amount of interleukin (IL)-6 was secreted by R837-activated pDCs from the two
groups of mice (Supplementary Figure S2). Surprisingly, no detectable IFN-α was observed in the
culture supernatant from R837-stimulated pDCs, whereas these pDCs were capable of producing
IFN-α upon CpG stimul tion. R837 is n imidazoquinoline amine analog to guanosine that commonly
used for evaluation of TLR7 media ed IFN-α response in human c lls and likely, R837 is inefficient in
activating type I IFN production in mice [31,32].
Apart from disease status, the age difference between the pre-symptomatic and symptomatic
NZB/W F1 mice could have contributed to the differential TLR7 response. To evaluate this,
R837 responses of pDCs derived from parental non-lupus NZW young (12–16 weeks old) and old
(>36 weeks old) mice were compared (Figure 4). Upregulation of MHC class II, CD40 as well as
CD86 on pDCs from both young and old NZW mice were induced and no significant differences
were observed between the two groups. These results suggested that the elevated R837 response in
symptomatic NZB/W F1 group was not likely attributed by the age factor.
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Figure 3. pDCs response to TLR7 stimulation is augmented in symptomatic mice. Purified BM-derived
pDCs from pre-symptomatic (Pre-sym) or symptomatic (Sym) NZB/W F1 mice were treated with (+)
or without (´) 5 µg/mL of R837 for 48 h. Expression of MHC class II, CD40 and CD86 were examined
and shown as representative histograms in (A). Grey: Isotype; dotted line: unstimulated; solid line:
R837 activated. Collective data illustrating changes in the mean fluorescence intensity (MFI) of
MHC class II, CD40 and CD86 or percentages (%) of the latter two are shown in (B,C) respectively.
Each symbol represents one experimental mouse. For expression of CD40, n = 12–13; CD86, n = 4–5;
MHC class II, n = 8. Data were collected from at least three independent experiments. Bar: mean value.
* p ď 0.05; ** p ď 0.01; (unpaired two-tailed Student’s t-test).
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2.4. TLR7 Mediated Overexpression of miR-155 in Lupus pDCs Contributes to the Heightened  
Cd40 Expression 
To identify potential regulator(s) involved in the enhanced TLR7 response in lupus pDCs,  
we examined miRNA expression profiles upon R837 stimulation and compared between  
pre-symptomatic and symptomatic mice. The miRNA rodent set array included a total of 750 targets, 
among which 107 were expressed in pDCs. The basal expressions of miRNAs in unstimulated pDCs 
from symptomatic mice were first compared with the pre-symptomatic one and no consistent 
difference in specific miRNA was observed in three independent sets of profiling experiments 
(Supplementary Figure S3). Next, the relative quantity (RQ) of the expressed miRNAs in  
R837-activated pDCs was compared between the pre-symptomatic and symptomatic groups  
(Figure 5A). With a two-fold change as cutoff, six specific miRNAs were found differentially 
expressed. In particular, miR-155 was the most strongly and consistently upregulated upon 
activation, and with a significantly higher induction in the symptomatic group. A higher induction 
of miR-132 was also observed in symptomatic pDCs. The other four miRNAs, miR-339-3p, miR-694, 
miR-421 and miR-103 were downregulated in symptomatic group with only marginal changes in  
pre-symptomatic one. Since the differential induction of miRNAs was most pronounced in miR-155, 
we decided to focus on this miRNA by further validation with independent sets of stimulation 
samples using miR-155 specific qPCR assay. Consistent with the array data, miR-155 was expressed 
at similar levels in both groups of unstimulated pDCs (Figure 5B), while R837-induced miR-155 
upregulation was significantly higher in the symptomatic group (23.44 ± 4.7 vs. 32.69 ± 4.5,  
Figure 5C). Furthermore, the R837-induced overexpression of miR-155 in pDCs of symptomatic 
NZB/W F1 mice was likely related to disease development since this difference was not observed 
when comparing young and old non-lupus NZW mice (Supplementary Figure S4). 
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e examined miRNA expression profiles upon R837 stimulation and compared between pre-symptomatic
and sy pto atic mice. The miRNA rodent set array included a total of 750 targets, among which 107
were expressed in pDCs. The basal ex ressions of miRNAs in unstimulated pDCs from symptomatic
mice were first compared with the pre-symptomatic one and no consistent difference in specific
miRNA was observed in three independent sets of profili g experiments (Sup leme tary Figure S3).
Next, the relative quantity (RQ) of the expressed miRNAs in 837-activated DCs was compared
between the pre-symptomatic and symptomatic groups (Figure 5A). With a two-fold change as
cutoff, six specific miRNAs were found differentially expressed. In particular, miR-155 was the most
strongly and consistently upregulated upon activation, a d with a sig ifica tly higher induction i
the symptomatic group. A higher inductio of miR-132 was also observed in symptomatic pDCs.
The other four miRNAs, miR-339-3p, iR-694, miR-421 and miR-103 were downregulated in
symptomatic group with only mar inal cha ges in pre-symptomatic one. Since the differential
induction f miRNAs was most pronounced in miR-155, we decided t focus n this miRNA by
further validation with independent sets of stimulation samples using miR-155 specific qPCR
assay. Consistent with the array data, miR-155 was expressed at similar levels in both groups of
unsti ulated pDCs (Figure 5B), while R837-induced miR-155 upregulation was sig ificantly higher
in the symptomatic group (23.44 ˘ 4.7 vs. 32.69 ˘ 4.5, Figure 5C). Furthermore, the R837-induced
overexpression of miR-155 in pDCs of sympt matic NZB/W F1 ice was likely related to dise se
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development since this difference was not observed when comparing young and old non-lupus NZW
mice (Supplementary Figure S4).Int. J. Mol. Sci. 2016, 17, 1282 8 of 17 
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Figure 5. Induction of miR-155 is e hanced in symptomatic pDCs upon TLR7 activation.
(A) Differential miRNAs expression profiles in R837-activated pDCs relative to unstimulated pDCs were
analyzed. Relative quantities (RQ) of expre sed miRNAs in symptomatic (Sym) group were plo ted
against pre-symptomatic (Pre-sym) group. The two bold lines indicate a cuto f of le s than two-fold
di ferences in expre sion. A rows indicate miRNAs that are di ferentia ly expre sed, whose mean RQ
of three independent repeats are presented in the table. Expre sion of iR-1 5 was independently
verified l ti e PCR on separ te samples of (B) unstimulated pDCs; and (C) R837-stimulated pDCs
from p e-symptomatic and symptomatic mice. Each symbol represents sampl from one experimental
mouse. Data were collected from three independent experiments, n = 5 for each group of F1 mice.
Bar: ean v lue. ** p ď 0.01 (unpaired two-tailed Student’s t-test).
In order to study hether the elevated iR-155 expression contributes to p C phenotypes
observed in sy pto atic ice, iR-155 i ics and scra ble/non-targeting controls were transfected
to pDCs derived fro pre-sy pto atic ice and d40 expression as easured. A significant
increase was observed for Cd40 expression upon iR-155 overexpression (Figure 6A). This is
consistent with the findings of an enhanced CD40 induction in symptomatic pDCs in response
to R837 stimulation in association with a higher miR-155 induction (Figures 3 and 5). In parallel,
the expression of SH2-containing inositol phosphatase Ship1, a known primary target of miR-155 [33],
as do nregulated ith a significant negative correlation with Cd40 in the iR-155 overexpressing
cells (Figure 6B).
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(A) Pre-symptomatic pDCs were transfected with miR-155 mimics or scramble mimics control
(control). The expression levels of Cd40 in miR-155-transfected pDCs were examined by real time
PCR and presented as relative quantity (RQ) to their respective mean expression in the control group.
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one experimental mouse. Data were collected from at least three independent experiments (n = 9).
3. Discussion
In this study, we have shown that in vitro derivation of pDCs from BM of symptomatic and
pre-symptomatic NZB/W F1 mice was comparable phenotypically, including the expression of TLR7
and TLR9. However, hypersensitivity of symptomatic pDCs to TLR7 stimulation was illustrated by
their increased upregulation of costimulatory molecules including CD40, CD86 as well as MHC class
II. Screening of miRNAs in pDCs revealed an enhanced induction of miR-155 in symptomatic mice
in response to TLR7 stimulation. Upon miR-155 overexpression, Cd40 expression was significantly
upregulated with a negative correlation to the miR-155 primary target Ship1 expression. Overall,
our findings suggest that the elevated miR-155 induction may contribute to the enhanced TLR7-induced
CD40 expression in pDCs derived from BM of lupus mice.
In SLE patients, BM abnormalities are not rare and reported features include hypocellularity,
necrotic alterations, reduced CD34+ HSC frequency as well as elevation of markers like CD95, CD123
and CD166 [21–23]. Such aberrations could be resulted from the disease itself and/or treatment using
immunosuppressive drugs. Based on our previous findings in BM-derived pDCs from patients [20],
we speculated that hypersensitivity in lupus pDCs could originate from abnormalities in BM precursors
as a result of the disease. In NZB/W F1 mice, despite the lack of gross aberrations in BM cells and HSC
frequency in symptomatic mice, BM-derived pDCs were indeed more sensitive to TLR7 stimulation
and showed higher CD40, CD86 and MHC class II induction. These observations are consistent
with the phenotypes observed in Flt3L-induced BM DCs from SLE patients [20]. Furthermore,
myeloid DCs derived from BM of old disease NZB/W F1 females also showed differential response
to estrogen modulation, leading to higher inflammatory cytokines production when compared with
young pre-disease mice [34]. Thus, it is likely that the common DC progenitors in BM of lupus patients
are modulated by disease parameters (e.g., perturbed cytokines levels) to give rise to hypersensitive
DCs that exit to the periphery.
In lupus, activation of pDCs can be constantly triggered by self-nucleic acids in complex
with autoantibodies or nuclear-binding proteins released from necrotic cells as well as activated
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neutrophils [35,36] via TLRs. The hyper-responsiveness to TLR7 stimulation in BM-derived pDCs in
symptomatic lupus-prone mice likely represents one of the pathological attributes for SLE development.
The pathogenic role of pDCs in lupus has been supported by recent evidence from selective depletion or
functional blockade of this cell population in lupus-prone mouse models [7,8,37]. It was demonstrated
that pDC deficiency in early disease development or the impairment of its function had beneficial effects
including reduced splenomegaly, anti-nuclear autoantibody production, reduced glomerulonephritis
and decreased levels of ISGs in kidney tissues [7,8]. In the tape-stripping model, depletion of pDCs
protected NZB/W F1 mice from developing chronic skin lesions and so did the treatment of TLR7 and
TLR9 inhibitors [37], suggesting that TLR7 and TLR9 signaling is important for lupus development.
Indeed, the duplicated Tlr7 gene, and hence the overexpressed receptor, in the BXSB male mice
promoted a biased response of autoreactive B cells toward nuclear self-antigens [38]. Introducing
the Tlr7-bearing yaa gene segment to B6.Sle1 mice also accelerated autoimmunity, in which the
disease severity positively correlated with the Tlr7 expression level [39]. The pathogenic role of
TLR9, however, is controversial. In fact, disparate contribution of TLR7 and TLR9 in SLE pathogenesis
has been reported. In B6.Nba2 congenic lupus mice, Tlr9 deletion led to accelerated lupus with
an increased production of anti-nuclear antibodies and augmented lupus nephritis, while disease
progression in the Tlr7/9 double-deficient mice was restored to a comparable or even slightly improved
level as the parental strain [40]. Our finding is in agreement with the critical involvement of TLR7
signaling pathway in pDC malfunction in SLE pathogenesis while little implication can be derived
from TLR9 response.
Despite having little baseline difference, the expression levels of CD40, CD86 and MHC class
II molecules were further augmented in symptomatic BM-derived pDCs upon TLR7 stimulation.
Consistently, splenic and lymph node pDCs in lupic NZB/W F1 mice have also been shown to display
elevated expression of costimulatory molecules, including CD40 and CD86 in pDCs when compared
with mice prior to disease onset [41,42], suggesting that the BM-derived pDCs bear similarities to
the peripheral circulating pDCs. Similarly, a recent report by Zhou et al. has also demonstrated in
disease NZB/W F1 mice a higher expression of MHC-II and CD80 in ex vivo splenic and BM pDCs
when compared with pre-disease mice [30]. Likely, these peripheral pDCs in disease mice have been
continuously exposed to and stimulated by TLR7 stimulating immune complexes in vivo, thus leading
to the hyperactivated phenotypes upon ex vivo examination. Functionally, it is conceivable that a
higher expression of CD86 and MHC class II could lead to better T cell stimulation by symptomatic
pDCs, and indeed this has been observed in SLE patients [19,20]. Enhanced CD40 expression in pDCs
may promote SLE development through its interaction with CD40L. Both soluble and cell-bound forms
of CD40L have been shown to increase significantly in SLE patients [43,44]. Interestingly, it has been
shown that activated platelets in lupus patient sera interact with pDCs through CD40L-CD40 signaling
and potentiate type I IFN secretion by pDCs [45]. CD40 signaling can also synergize TLR9-induced
type I IFN response in pDCs [46]. With the increased pDC hypersensitivity we found here and
reported elsewhere, we believe that pDCs could potentially function as an accelerator to promote SLE
development, at least in part through the increased CD40 expression upon TLR7 activation.
Previous miRNA profiling analyses in SLE were mainly done in total PBMCs from patients
or total splenocytes and lymphocytes from murine models in unstimulated condition [12,47,48].
Here, changes in the miRNA expression were examined in purified pDCs upon TLR7 stimulation,
and the heightened miR-155 induction was shown to mediate enhanced Cd40 expression in
symptomatic pDCs. This finding is in line with another study, which reported a decrease in MHC
class II, CD40, and CD86 expressions in miR-155 knockdown Kupffer cells [49]. It is not clear how
miR-155 mediates an increase in CD40 expression in pDCs. We observed a significant negative
correlation between Cd40 and Ship1 expression in pDCs upon miR-155 modulation. SHIP1 is a
negative immuno-regulator and has been shown to suppress TLR4 response via MyD88 in DCs [50].
Consistently, a recent report shows that miR-155 upregulation in DCs can lead to breaking of T cell
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tolerance by negative regulation of SHIP1 [51]. However, pertaining to this study, whether there is a
functional correlation between CD40 and SHIP1 in pDCs is yet to be determined.
Our findings are consistent with the pro-autoimmune nature of miR-155, at least in the murine
models. Notably, an upregulation of miR-155 was demonstrated in total splenocytes in different
lupus mouse models, and was further shown in the splenic T and B lymphocyte compartments [48].
In MRL/lpr lupus mice, an enhanced miR-155 expression in CD4+CD25+Foxp3+ Treg cells was found
in association with a compromised Treg suppressive function [52]; and the deletion of miR-155
in these mice alleviated lupus-like disease [53]. Besides, miR-155 appears to play a pathogenic
role in other autoimmune diseases too. Silencing or depleting miR-155 in the mice protected them
from developing experimental autoimmune encephalomyelitis or collagen-induced arthritis [54–56].
The miR-155-deficient mice in both of these models had impaired Th17 cell development and reduced
proinflammatory Th1 and Th17 cytokines, suggesting a pathogenic contribution of miR-155 in T-cell
mediated autoimmunity. Our study also suggests a pathogenic role of miR-155 in mediating pDC
abnormality in the NZB/W F1 lupus model.
We identified a novel regulation of CD40 expression by miR-155, by which may contribute
to the hyperactivated TLR7 response in lupus pDCs. Pertaining to our findings, more questions
arise and warrant further exploration. First, it is not clear how the symptomatic BM-derived pDCs
mediate higher TLR7 responses. We evaluated TLR7 as well as its downstream transcription factor
Irf7 expression levels and found no difference. Thus, other TLR7 downstream signaling networks
(e.g., NF-κB and c-JNK pathways) should be examined. So far, the regulation of TLR7
(and TLR9) signaling network in pDCs remains elusive and can be influenced by other pDC-specific
receptor-mediated signaling pathways [57]. A potential cross-regulation between TLR7 signaling and
miR-155 would worth studying. In human pDCs, miR-155 and miR-155* are induced at different
kinetics upon R837 stimulation [15]. Interestingly, miR-155 seems to act as a negatively regulator in
type I IFN production by targeting TAB2 while miR-155* augments IFNα/β production by targeting
IRAKM. In murine pDCs, R837 stimulation also upregulates miR-155 but cannot elicit IFNα production.
We also found that miR-155 overexpression had minimal impact on Tab2 expression (data not shown).
In our miRNA screening assay, miR-155-3p (star form) was not included, and whether its expression
changes upon TLR7 stimulation remains to be determined. It is likely that if a cross regulatory
mechanism between murine TLR7 and miR-155 exists, it would be different from that found in human
cells. In contrast to costimulatory molecules expression, it is not clear why the R837-induced IL-6
appears not be affected in symptomatic pDCs. For TLR9 stimulation, different CpG oligonucleotides
elicit disparate functional outcomes depending on the nature of the phosphorothioated backbone
as well as the presence of palindromic sequences. Class A CpG is an efficient type I IFN inducer
while class B is more superior in inducing costimulatory molecules and cytokines expression in B
cells, each triggering distinct regulatory pathways [46]. It is possible that different TLR7 agonists
(e.g., ss-PolyU) may yield different response outcomes in our study system. More studies are therefore




The NZW/LacJ and NZB/BlNJ strains were purchased from The Jackson Laboratory (Bar Harbour,
ME, USA). Breeding of the NZB/W F1 hybrid mice was carried out at The Laboratory Animal
Unit, The University of Hong Kong. Licenses specifying experiments involved in this study were
obtained from the Department of Health, Hong Kong. All experimental protocols and procedures
were approved by the University Committee on the Use of Live Animals in Teaching and Research
(CULATR 2213-10, approved on 5 August 2010 and CULATR 2449-11, approved on 25 May 2011).
Lupus disease development in female NZB/W F1 mice and age-matched female NZW control mice
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was monitored. Serum levels of anti-dsDNA IgG autoantibodies were measured bi-weekly by ELISA.
Proteinuria was measured weekly by Albutix stripes (Bayer HealthCare, Leverkusen, Germany).
Aged (>25 weeks old) NZB/W F1 mice with persistent proteinuria (+++, 3 mg/mL or above for
over 2 weeks) and anti-dsDNA IgG levels higher than two standard deviations (SD) over the mean of
the age-matched NZW mice were considered as symptomatic. Young (8–15 weeks old) NZB/W F1
mice with anti-dsDNA levels comparable to non-lupus NZW control mice and negative for proteinuria
were considered pre-symptomatic.
4.2. pDC Culture, Isolation and Stimulation
BM-derived pDCs were cultured as previously described with some modifications [24,28].
Briefly, total BM cells were harvested by flushing humeri, tibias and femurs of mice. Red blood cells
were lysed using ACK buffer (0.15 M NH4Cl, 0.01 M KHCO3, 0.1 mM EDTA) and BM cells were seeded
in 12-well plates at 5 ˆ 106 cells/mL in 10% fetal bovine serum in complete IMDM supplemented
with 100 ng/mL of mouse Flt3 ligand (Peprotech, Rocky Hill, NJ, USA). In some experiments,
hematopoietic stem cells were enriched before culture using the mouse lineage cell depletion kit
(Miltenyi Biotec, Bergisch Gladbach, Germany). On day-8, cells were stained with appropriate
antibodies and pDCs were purified by fluorescence-activated cell sorting using the Beckman Coulter
MoFlo™ XDP cell sorter for subsequent experiments. Purified pDCs were seeded at 5 ˆ 104 cells/well
in 96-well plates with 5 µg/mL of R837 (Imiquimod), 1 µM of CpG (InvivoGen, San Diego, CA, USA)
or medium only (unstimulated) for 48 h, or specified otherwise. Stimulated cells were stained for
activation markers and analyzed using the BD FACSCanto II Analyzer at Faculty Core Facilities,
Li Ka Shing Faculty of Medicine, The University of Hong Kong. For staining of TLR7 and TLR9,
day-8-BM cultures were first surface-stained for CD11c and B220, followed by fixation with 4%
paraformaldehyde and permeabilization with 0.2% saponin. Intracellular staining was performed
in the presence of 0.2% saponin throughout. The following anti-mouse monoclonal antibodies
(BD Biosciences or Affymetrix eBiosciences, Franklin Lakes, NJ, USA) were used in this study:
Sca-1-FITC (clone: D7); c-Kit-PE (2B8); CD11c-FITC (HL3); B220-APC or PECy7 (RA3-6B2); Siglec-H-PE
(eBio440c); CD317-APC (eBio927); CD40-PE (3/23); CD86-PE or PECy7 (GL1); MHC class II—PECy7
(M5/114.15.2); TLR7-PE (A94B10) and TLR9-PE (J15A7).
4.3. Transfection of miRNA Mimics
Double-stranded miRNA mimics or scramble controls (GenePharma, Shanghai, China) were
transfected into BM-derived pDCs using the Lipofectamine 2000® reagent (Invitrogen, Thermo Fisher
Scientific, Waltham, MA, USA) at 100 nM for 4 h at 37 ˝C. Total RNAs of the transfected cells
were extracted using TRI reagent (Sigma-Aldrich, St. Louis, MO, USA) and stored at ´80 ˝C for
subsequent experiments.
4.4. Quantitative Real-Time RT-PCR
Quantitative gene expression analyses were performed following the Minimal Information for
Publication of Quantitative Real-time PCR Experiments (MIQE) guidelines. Total cellular RNAs were
extracted using TRI Reagent® (Sigma-Aldrich, St. Louis, MO, USA) and then reverse transcribed into
cDNAs with the ThermoScript™ RT-PCR system (Invitrogen, Thermo Fisher Scientific, Waltham, MA,
USA) according to the manufacturer’s recommendation. Amplification of cDNAs was carried out
using the StepOnePlus™ system and StepOne Software v2.3 (Applied Biosystems®, Thermo Fisher
Scientific, Waltham, MA, USA) with KAPA SYBR® Fast qPCR kit (Kapa Biosystems, Wilmington, MA,
USA) following the thermal conditions at: 95 ˝C for 3 min and 40 cycles of 95 ˝C, 60 ˝C and 72 ˝C for
20 s each. Relative quantity (RQ) of gene-of-interest was normalized with β-actin and calculated using
the formula: RQ = 2´[∆Cq (test sample)´ ∆Cq (reference sample)]. The primers for specific targets tested in this
study are listed in Table 1. The amplification efficiency of each pair of primers was validated and was
comparable to that of the endogenous control. In all experiments, no template control and melting
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curve analyses of the amplification products were included. Independent quantification of miR-155
was carried out using the miRNA assay (assay ID 002571 specific for mmu-miR-155) purchased from
Applied Biosystems® (Thermo Fisher Scientific, Waltham, MA, USA). Reactions and thermal conditions
of quantitative real-time PCR for miR-155 were performed following manufacturer’s recommendation.
Table 1. List of primers used in this study.
Gene Sequence Accession No. Tm Pdt Location
β-actin Fwd TTG CTG ACA GGA TGC AGA AG NM_007392.3 58.2 147 1039–1058Rev TGA TCC ACA TCT GCT GGA AG – 57.3 – 1185–1166
Irf7 Fwd GAT CTT CAA GGC CTG GGC TGT GG NM_016850.3 57.1 220 611–633Rev TCC AAG CTC CCG GCT AAG TT – 55.0 – 830–811
Ifitm3 Fwd GAT CGG CTT CTG TCA GAA CTA NM_025378.2 57.2 154 209–229Rev TTC CGA TCC CTA GAC TTC ACG GA – 62.5 – 362–340
Tlr7 Fwd TGT TAC TAT TCC ATA CCT GGC CAC NM_133211.4 60.1 179 2640–2663Rev GGT GAC TTG TTG TCA TAA CTA CC – 57.1 – 2818–2796
Tlr9 Fwd CAA CAT GGT TCT CCG TCG AA NM_031178.2 58.2 243 103–122Rev TTG TGC AGG TGG TGG ATA CGG T – 64.2 – 345–324
Cd40 Fwd TTG TTG ACA GCG GTC CAT CT NM_011611.2 59.6 154 112–131Rev CTG AGT CAC ATG GGT GGC AT – 60.0 – 265–246
Ship1 Fwd CCA GGG CAA GAT GAG GGA GA NM_001110193.2 60.98 195 2766–2785Rev GGA CCT CGG TTG GCA ATG TA – 60.04 – 2960–2941
Fwd: forward primer; Rev: reverse primer; Tm: melting temperature; Pdt: size of the amplification product in
base pair. Final concentration of primer used in qPCR was 200 nM.
4.5. MicroRNA Profiling
Extracted total RNAs were reverse transcribed using the Megaplex™ RT primers, Rodent pool A
and B sets and the TaqMan® miRNA reverse transcription kit. Subsequently, cDNAs were pre-amplified
using the Megaplex™ PreAmp Primers and the TaqMan® PreAmp Master Mix. Pre-amplified products
were mixed with TaqMan® Universal PCR master mix (No AmpErase® UNG) in suggested ratio
following the manufacturer’s recommendation and then loaded to the 384-well TaqMan® Array
Rodent miRNA A and B Cards. The reactions were performed on 7900HT Real-Time PCR System
at The Centre for Genomic Sciences, The University of Hong Kong. Results were analyzed using
Sequence Detection Systems v2.4 and RQ Manager V1.21. The reagents and analysis software used for
the arrays were purchased from Applied Biosystems® (Thermo Fisher Scientific, Waltham, MA, USA).
The expression of each miRNA was normalized with the mammalian U6 internal control, and RQ was
calculated using the formula: RQ = 2´[∆Cq (test sample)´ ∆Cq (reference sample)].
4.6. Statistical Analysis
Unless specified, all experimental data were presented as mean values˘ SD. Statistical significance
was determined by unpaired two-tailed Student’s t-test, and correlation analysis by linear regression
using GraphPad Prism (GraphPad, Inc., San Diego, CA, USA).
5. Conclusions
Using the NZB/W F1 murine lupus model, we unraveled a miR-155-associated hyperactive
TLR7 response in BM-derived pDCs after the onset of lupus. The expression of Cd40 is upregulated
upon overexpression of miR-155 in pDCs. In essence, the current study highlights the elevated
pDC responses to TLR7 stimulation in lupus and suggests a potentially pathogenic role mediated by
miR-155. We present here the connection between miRNA and the hyperactivation of pDCs including
the upregulation of CD40. Findings in this study shed light on the potential roles of pDCs in the
pathogenesis of SLE.
Supplementary Materials: The following are available online at www.mdpi.com/1422-0067/17/8/1282/s1.
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